Summary: New research highlights the neurotransmitter GABA and its principal receptors, particularly GABA-A receptors, as promising targets for treating depressive disorders. The authors describe potential mechanisms by which therapies that modify GABA signaling could relieve both mood-related and cognitive symptoms of depression.
The review brings together evidence that drugs which either enhance or transiently inhibit GABA-A receptor function may produce antidepressant effects, underscoring the need for a more nuanced understanding of how GABAergic modulation can be used to treat depression.
This paper represents an important advance in considering GABA-A receptors as therapeutic targets for affective and cognitive symptoms associated with depression.
Key Facts:
- GABA and its main receptor, GABA-A, play a significant role in depressive disorders and offer promising targets for new therapies.
- Modulating GABAergic signaling can potentially address both cognitive impairments and mood symptoms often experienced in depression.
- Both agents that enhance and those that transiently suppress GABA-A receptor activity appear to have antidepressant potential, highlighting the complex neurobiology underlying depression and treatment response.
Source: University of Illinois
Depression is a multifaceted condition linked to multiple changes in brain circuits and signaling mechanisms.
A new review synthesizes existing research on the inhibitory neurotransmitter GABA and its primary receptors, presenting evidence that GABA-A receptors are important contributors to depressive disorders and promising targets for therapeutic intervention.
Drawing on findings from molecular, cellular, animal, and clinical studies, the authors outline plausible pathways through which GABA-modulating treatments could improve both cognitive function and mood symptoms associated with depression.
The review was authored by Bernhard Luscher (Penn State University), Jamie Maguire (Tufts University), Uwe Rudolph (University of Illinois Urbana-Champaign), and Etienne Sibille (University of Toronto and the Centre for Addiction and Mental Health) and published in the journal Trends in Pharmacological Sciences.
Most current antidepressants focus on increasing serotonin function, but research over the past two decades has revealed greater complexity. GABA and GABA-A receptors now appear to play a substantive, though not yet fully understood, role in depression.
“Defects in GABA signaling and GABA-A receptor function have long been suspected to contribute to depressive disorders,” said Bernhard Luscher, who first produced strong experimental evidence linking GABA dysfunction to depression in 2010 using mouse models.
The clinical relevance of GABAergic modulation was reinforced in 2019 when the FDA approved brexanolone for peripartum depression. Brexanolone is a synthetic neuroactive steroid that primarily enhances GABA signaling at GABA-A receptors, and similar compounds have shown benefit in trials for broader forms of major depressive disorder.
GABA acts as the brain’s chief inhibitory chemical messenger, balancing excitatory signals and helping prevent overactivity in neural circuits.
“Neural networks require both excitation and inhibition to function properly—too much or too little of either can impair processing,” said Uwe Rudolph.
Neurosteroids are endogenous compounds that positively modulate GABA-A receptors. Chronic stress, a major risk factor for depression, reduces neurosteroid signaling and disrupts inhibitory balance. Restoring neurosteroid action can strengthen GABAergic inhibition and improve behavioral outcomes, supporting the idea that neurosteroid regulation of GABA-A receptors influences mood.
Jamie Maguire emphasized that impaired neurosteroid signaling is implicated in depression and that treatments stimulating GABA-A receptors may produce antidepressant effects by correcting this underlying mechanism.
A puzzling observation from preclinical work is that both enhancers and inhibitors of GABA-A receptor function can show antidepressant-like effects. In their review, the authors propose mechanisms that reconcile these findings: gradual enhancement of GABA-A function can correct deficits in inhibitory tone seen in aging or chronic stress, while acute, transient inhibition of certain GABA-A receptor populations can allow brain circuits to rapidly reset from pathological states.
Agents that potentiate GABA-A receptors generally dampen neuronal excitability and may be effective when depression is associated with excessive circuit activity or impaired inhibition. In contrast, brief inhibition of GABA-A receptors can transiently increase neuronal activity and trigger network changes that relieve depressive states more rapidly.
The review also argues that targeting GABA-A receptors may address cognitive deficits frequently seen in depression—deficits that are often resistant to treatments aimed solely at serotonin or other neurotransmitters. Work from Etienne Sibille’s laboratory links GABAergic impairments to cognitive dysfunction in depression and other disorders such as Alzheimer’s disease. Their studies combined observations from human postmortem tissue with causal demonstrations in animal models.
These findings have supported translational efforts, including the formation of a biopharmaceutical company focused on developing treatments for cognitive deficits across brain disorders.
Overall, the body of evidence reviewed—ranging from receptor biology and neurosteroid effects to clinical success with brexanolone—supports GABA-A receptors as an important target for treating both mood and cognitive symptoms of depression. The authors conclude that therapies directed at specific GABA-A receptor subtypes and signaling mechanisms deserve further clinical investigation.
About this neuroscience and depression research news
Author: Liz Ahlberg Touchstone
Source: University of Illinois
Contact: Liz Ahlberg Touchstone – University of Illinois
Image: The image is credited to Neuroscience News
Original Research: Open access. “GABAA receptors as targets for treating affective and cognitive symptoms of depression” by Bernhard Luscher et al., Trends in Pharmacological Sciences.
Abstract
GABAA receptors as targets for treating affective and cognitive symptoms of depression
- A neuroactive steroid (NAS) that targets δ-containing GABA-A receptors has been approved for peripartum depression, and clinical trials are underway to evaluate NASs for major depressive disorder.
- Preclinical studies show that both positive and negative modulators of α5-containing GABA-A receptors can produce antidepressant-like effects. The review discusses a model explaining how bidirectional modulation of the same receptor population may yield antidepressant outcomes.
- The authors propose a model by which positive allosteric modulation of α5-GABA-A receptors improves the signal-to-noise ratio in cortical microcircuits, thereby restoring information processing and cognitive function.